ArticleCancers2023

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study.

Francesca Palandri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.